Transcode Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Transcode Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q2 2024.
  • Transcode Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$5.19M, a 19.6% decline year-over-year.
  • Transcode Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$17.9M, a 3.64% increase year-over-year.
  • Transcode Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$18.5M, a 5.59% decline from 2022.
  • Transcode Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$17.6M, a 157% decline from 2021.
  • Transcode Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$6.84M, a 192% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$17.9M -$5.19M -$849K -19.6% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$17.1M -$3.33M +$1.49M +30.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-14
Q4 2023 -$18.5M -$4.09M +$1.05M +20.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-01
Q3 2023 -$19.6M -$5.3M -$1.01M -23.6% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 -$18.6M -$4.34M +$330K +7.06% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$18.9M -$4.82M -$1.35M -38.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-14
Q4 2022 -$17.6M -$5.13M -$2.33M -83.4% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-01
Q3 2022 -$15.2M -$4.29M -$1.96M -84.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$13.3M -$4.67M -$7.44M -269% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-14
Q1 2022 -$5.83M -$3.47M +$1.02M +22.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-14
Q4 2021 -$6.84M -$2.8M -$2M -249% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$4.85M -$2.33M -$956K -69.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$3.89M $2.77M +$2.9M Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-14
Q1 2021 -$6.79M -$4.49M -$4.44M -10771% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-14
Q4 2020 -$2.34M -$802K Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 -$1.37M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$127K Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-15
Q1 2020 -$41.3K Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.